Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

Cadrenal Therapeutics (CVKD) acquired VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. The acquisition ...

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...

Novartis has reported positive outcomes from the VAYHIT2 Phase III trial assessing ianalumab plus eltrombopag to treat ...

One of the side effects of aspirin is reduced platelet function. Aspirin can potentially make issues with blood clotting worse. Thrombocytopenia is the medical term for low platelet count. Platelets ...